Clinical Trial Update: Study of Durvalumab Given With Chemotherapy, Durvalumab in Combination With Tremelimumab Given With Chemotherapy, or Chemotherapy in Patients With Unresectable Urothelial Cancer [Phase 3]

View source ↗

Summary

Phase 3 study evaluating durvalumab with chemotherapy, durvalumab plus tremelimumab with chemotherapy, or chemotherapy alone in patients with unresectable or me…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• Durvalumab (durvalumab)
• Tremelimumab (tremelimumab)

Snippet

Sponsor: AstraZeneca | Conditions: Unresectable Locally Advanced Urothelial Cancer, Metastatic Urothelial Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING